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Abstract: Background. The KEAP1/NRF2 pathway has been widely investigated in tumors since it
was implicated in cancer cells survival and therapies resistance. In lung tumors the deregulation
of this pathway is mainly related to point mutations of KEAP1 and NFE2L2 genes and KEAP1
promoter hypermethylation, but these two genes have been rarely investigated in low/intermediate
grade neuroendocrine tumors of the lung. Methods. The effects of KEAP1 silencing on NRF2
activity was investigated in H720 and H727 carcinoid cell lines and results were compared with
those obtained by molecular profiling of KEAP1 and NFE2L2 in a collection of 47 lung carcinoids.
The correlation between methylation and transcript levels was assessed by 5-aza-dC treatment.
Results. We demonstrated that in carcinoid cell lines, the KEAP1 silencing induces an upregulation of
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NRF2 and some of its targets and that there is a direct correlation between KEAP1 methylation and its
mRNA levels. A KEAP1 hypermethylation and Loss of Heterozygosity at KEAP1 gene locus was also
observed in nearly half of lung carcinoids. Conclusions. This is the first study that has described the
effects of KEAP1 silencing on the regulation of NRF2 activity in lung carcinoids cells. The epigenetic
deregulation of the KEAP1/NRF2 by a KEAP1 promoter hypermethylation system appears to be a
frequent event in lung carcinoids.
Keywords: Lung Carcinoid; KEAP1; NRF2; methylation; mutation; outcome
1. Background
The KEAP1 (Kelch-like ECH-associated protein 1)/NRF2 (Nuclear factor (erythroid-derived 2)-like
2) is a master pathway regulator of antioxidants and cellular stress responses and is clearly implicated
in neoplastic progression and resistance of tumor cells against chemo- and radio-treatments [1], so
the consequent enhancement of NRF2 expression is becoming a new potential target of anticancer
therapeutic approaches [2].
In solid tumors, both genetic and epigenetic mechanisms are described to play a significant role
in the impairment of KEAP1/NRF2 activity. In lung cancer, promoter KEAP1 methylation and point
mutations in functional domains of KEAP1 and NFE2L2 genes are firstly reported in NSCLC [3,4] and
then widely described as a specific signature of aggressiveness in many solid tumors, being correlated
with overall survival and response of patients to standard treatments [5,6]. On the other side, molecular
data regarding the deregulation of redox axis in pulmonary neuroendocrine tumors (lung NETs) are
limited, even if several important indications have emerged in recent years. Specifically, the KEAP1
genetic alterations were described by Fernandez-Cuesta et al. as a new uncovered molecular hallmark of
the Lung LCNEC (Large Cell Neuroendocrine Carcinoma) group with adenocarcinoma-like features [7].
A lack of evidence suggest an important question that needs to be addressed when considering the
alterations of KEAP1-NRF2 pathway in the other lung NETs and the impact of NRF2-related targets in
the epigenetic context of lung neuroendocrine carcinoma.
Carcinoids are rare neuroendocrine tumors of the lung with a low mutation rate and few
recurrently mutated genes, mainly clustered in the genes involved in chromatin remodeling events,
such as acetylation and methylation [8,9]. Epigenetic marks in carcinoids are poorly investigated and
DNA methylation of few genes are reported to have a prognostic value in the context of typical and
atypical lung carcinoids [10,11].
No somatic mutations in KEAP1 and NFE2L2 genes were identified by a unique WES study
performed to date in a limited cohort of patients [8], and no investigations have been performed until
now about the epigenetic status of the KEAP1 promoter region both in typical (TC) and in atypical
carcinoids (AC), [12].
We aim to investigate the effects of KEAP1 on NRF2 modulations and the existing molecular
background of this pathway in low/intermediate grade lung NETs by evaluating the effects of KEAP1
silencing on NRF2 and its target activity in carcinoid cell lines. Additionally, we perform the first
epigenetic profile of KEAP1 promoter region in lung carcinoid tissues together with the genetic
screening of the KEAP1 and NFE2L2 genes and LOH analysis.
2. Results
2.1. The KEAP1 Silencing Affects the NRF2 and Expression Levels of TXNRD1, AKR1C1 and NQO1 in
Carcinoid Lines
NRF2 activation was determined in H720 cells with transient silencing of the KEAP1 gene.
Following KEAP1 siRNA transfection, the protein level of NRF2 showed a significant up-regulation
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compared to NRF2 levels of Scrambled siRNA transfection, both in H720 and in H727 cell lines
(* p < 0.05 and p < 0.001, t-test). Consistent with the increase of NRF2 levels in both cell lines, in the
H720 cell line AKR1C1 and NQO1 ARE-dependent genes were significantly higher in KEAP1-Knock
Down cells than SCR cells, whereas in the H727 cell line we observed a significant increase of TXNRD1,
AKR1C1 and NQO1 protein levels after KEAP1 silencing (Figure 1).
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Figure 1. (A) Representative Western Blots analysis showing expression levels of KEAP1, NRF2, 
AKR1C1 and TXNRD1 in H720 and 727 cell lines after KEAP1 inhibition by specific KEAP1 siRNA. 
Scrambled siRNA was performed as the control. (B) Histograms show the expression levels of the 
proteins normalized to actin (N = 4). No overexposure was done. The grouping of gels/blots were 
cropped from different parts of the same gels. * p < 0.05, ** p < 0.001, *** p < 0.0001 t-test. 
2.2. Restoration of KEAP1 Expression Correlates with KEAP1 P1 Region Demethylation by 5-aza-dC 
Treatment in Carcinoid Cell Lines 
A genetic and epigenetic H720 and H727 was assessed and no mutations in KEAP1 or NFE2L2 
genes were found. By contrast, an aberrant KEAP1 promoter methylation was observed in the H720 
cell line compared with H727, which reflects the KEAP1 mRNA expression level in the two lines 
(Figure 2A). 
Figure 1. (A) Representative Western Blots analysis showing expression levels of KEAP1, NRF2,
AKR1C1 and TXNRD1 in H720 and 727 cell lines after KEAP1 inhibition by specific KEAP1 siRNA.
Scrambled siRNA was performed as the control. (B) Histograms show the expression levels of the
proteins normalized to actin (N = 4). No overexposure was done. The grouping of gels/blots were
cropped from different parts of the same gels. * p < 0.05, ** p < 0.001, *** p < 0.0001 t-test.
2.2. Restoration of KEAP1 Expression Correlates with KEAP1 P1 Region Demethylation by 5-aza-dC
Treatment in Carcinoid Cell Lines
A genetic a d epigenetic H720 and H727 was assessed and no mutations in KEAP1 or NFE2L2
genes were found. By contrast, an aberrant KEAP1 promoter methylation was observed in the H720
cell line compared with H727, which reflects the KEAP1 mRNA expression level in the two lines
(Figure 2A).
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Figure 2. (A) Expression level analysis (± standard error mean) of the KEAP1 gene in H720 and H727 
determined by RT-qPCR. The relative quantification was expressed as the ratio marker 
(KEAP1/RPLPO). (B) Methylation levels (± standard error mean) of KEAP1 in H720 and H727 
determined by qMSP (N = 4). * p < 0.05, *** p < 0.0001 t-test. 
The real effect of promoter CpG methylation on the modulation KEAP1 mRNA expression level 
was observed in the atypical carcinoid H720 hypermethylated cell line under 5-aza-dC treatment. 
The variation of methylation and KEAP1 mRNA level was examined before and during the 
demethylating treatment (Figure 3A) by RT-qPCR and qMSP. A progressive significant increase of 
the KEAP1 transcript abundance was observed after 24h (p < 0.01) and 48h (p < 0.01) concomitantly 
with a decreased KEAP1 promoter methylation at both time points (p < 0.01), (Figure 3B). 
  
Figure 2. (A) Expression level analysis (± standard error mean) of the KEAP1 gene in H720 and H727
determined by RT-qPCR. The relative quantification was expressed as the ratio marker (KEAP1/RPLPO).
(B) Methylation levels (± standard error mean) of KEAP1 in H720 and H727 determined by qMSP
(N = 4). * p < 0.05, *** p < 0.0001 t-test.
The real effect of promoter CpG methylation on the modulation KEAP1 mRNA expression level
was observed in the atypical carcinoid H720 hypermethylated cell line under 5-aza-dC treatment.
The variation of methylation and KEAP1 mRNA level was examined before and during the
demethylating treatment (Figure 3A) by RT-qPCR and qMSP. A progressive significant increase
of the KEAP1 transcript abundance was observed after 24h (p < 0.01) and 48h (p < 0.01) concomitantly
with a decreased KEAP1 promoter methylation at both time points (p < 0.01), (Figure 3B).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 18 
 
 
 
Figure 3. (A) Changes in KEAP1 mRNA transcript levels in the H720 cell line before (Untreated) and 
after treatment with 5-aza-dC at 24 h and 48h. Error bars indicate the standard deviation of three 
different experiments. * p < 0.01, t-test. (B) Changes in KEAP1 promoter methylation levels in the H720 
cell line by quantitative methylation real-time PCR before (CTRL) and after treatment with 5-aza-dC 
at 48 and 72 h. Error bars indicate the standard deviation of three different experiments.* p < 0.05, t-
test. 
2.3. KEAP1 Promoter Region Hypermethylation are Frequent Epigenetic in Lung Carcinoids, Whereas Point 
Mutations are Absent. 
The KEAP1 promoter methylation level was evaluated on DNA obtained from a total of all lung 
carcinoid tissues and 12 normal lung tissues from non-neoplastic patients (NL). The median values 
and Inter Quartile Ranges (IQR) for KEAP1/ACTB ratios were 0.0 (0-0) for NL, as a consequence all 
positive values in tumor tissues were considered to be equal to a hypermethylated status. In TC 
KEAP1 methylation was detected in 15 out of 30 cases (50%), while in AC methylation was detected 
in 8 out of 17 cases (47%). No statistically significant differences in methylation levels assessed by 
qMSP were detected between the TC and AT groups. 
To ascertain the status of the KEAP1 locus we genotyped 17 tumors (5 ACs and 12 TCs) of the 
cohort and their corresponding peripheral blood/normal tissues using the D19S865, DM1, D19S906 
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Figure 3. (A) Changes in KEAP1 mRNA transcript levels in the H720 cell line before (Untreated) and
after treatment with 5-aza-dC at 24 h and 48h. Error bars indicate the standard d viation of three
different experiments. * p < 0.01, t-test. (B) Changes in KEAP1 promoter methylation level i the H720
cell line by quantitative methylation real-time PCR before (CTRL) and after treatment with 5-aza-dC at
48 and 72 h. Error bars indicate the standard deviation of t ree diffe nt experiments. * p < 0.05, t-test.
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2.3. KEAP1 Promoter Region Hypermethylation are Frequent Epigenetic in Lung Carcinoids, Whereas Point
Mutations are Absent
The KEAP1 promoter methylation level was evaluated on DNA obtained from a total of all lung
carcinoid tissues and 12 normal lung tissues from non-neoplastic patients (NL). The median values
and Inter Quartile Ranges (IQR) for KEAP1/ACTB ratios were 0.0 (0-0) for NL, as a consequence all
positive values in tumor tissues were considered to be equal to a hypermethylated status. In TC KEAP1
methylation was detected in 15 out of 30 cases (50%), while in AC methylation was detected in 8 out of
17 cases (47%). No statistically significant differences in methylation levels assessed by qMSP were
detected between the TC and AT groups.
To ascertain the status of the KEAP1 locus we genotyped 17 tumors (5 ACs and 12 TCs) of the
cohort and their corresponding peripheral blood/normal tissues using the D19S865, DM1, D19S906 and
D19S2840 microsatellite markers located at the 19p13.2 locus. As a result, 3/5 AC (60%) and 6/12 (50%)
TC groups demonstrated LOH for at least one of the markers (Table 1). An alternative mechanism to
achieve the deregulation of KEAP1 would be the occurrence of somatic mutations in our Carcinoid
samples. Despite the literature evidence, to exclude this possibility we analyzed all carcinoid cohorts,
searching for somatic alterations in the whole coding region of the KEAP1 gene and in the Neh2 domain
of the NFE2L2 gene. This analysis did not reveal any sequence variations that would likely result in a
functional alteration in the KEAP1 or NRF2 proteins.
To assess the possible correlation between the KEAP1 protein levels in carcinoid and the epigenetic
silencing of the KEAP1 gene, 11 tumor cases (3 AC and 8 TC) showing KEAP1 promoter methylation
and 3TC tumors without aberrant methylation were analyzed by immunohistochemical analysis.
All the areas of the tissue section were evaluated for KEAP1 protein expression. A variable KEAP1
immunoreactivity was observed in the cytoplasm of tumor cells but no statistically significant differences
were observed. Only in a few cases was it possible to notice a direct relationship among KEAP1
downregulation and overexpression of NRF2 and its target TXNRD1 and NQO1 (Figure 4).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 18 
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Figure 4. Immunohistochemistry analysis showing KEAP1, NRF2, TXNRD1 and NQO1 proteins
expression in one typical (unmethylated, A–D) and one atypical (methylated, E–H) lung tissue from
two different carcinoid affected patients. 20× and 40×magnification. A strong KEAP1 cytoplasmatic
staining was observed in a typical unmethylated lung carcinoid tissue with a mild nuclear NRF2 and
cytoplasmatic TXNRD1 and NQO1 staining, whereas an inverse protein staining pattern was observed
in an atypical methylated lung carcinoid tissue.
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Table 1. Clinical-pathological features of lung carcinoid samples harboring KEAP1 molecular lesions.
ID Sample HistotypesGender
KEAP1
(Meth and/or
LOH 1)
Years at
Diagnosis
UICC
Stage
Progression
(Y/N)
Status
(D/A)
DFS
(mos)
OS
(mos)
LCCH01-322 AC M Meth 52 IIA Y A 84 120
LCCH01-328 AC M LOH 47 IIA N A 67 67
LCCH01-329 AC M LOH 49 IA N A 124 204
LCCH01-330 AC F Meth 67 IB N A 142 142
LCCH01-378/85 AC M Meth 71 IA Y D 12 23
UD-3 AC M Meth 44 IB Y D 60 132
UD-7 AC M Meth 61 IB N A 84 84
UD-18 AC F Meth 35 IB Y A 36 120
UD-20 AC F Meth 69 IIIA N A 108 108
UD-24 AC F Meth 69 IB Y D 12 28
LCCH01-315 TC M Meth, LOH 54 IA N A 203 288
LCCH01-377/35 TC F Meth, LOH 35 IB N A 52 52
LCCH01-313 TC F LOH 57 IA N A 36 36
LCCH01-327 TC M Meth, LOH 69 IA N A 66 66
LCCH01-320 TC F Meth 29 IB N A 157 157
LCCH01-323 TC F Meth, LOH 70 IA N A 132 132
LCCH01-325 TC F Meth 36 IA N A 124 124
LCCH01-327 TC M Meth 69 IA N A 66 66
LCCH01-321bis/380 TC M Meth 48 IB N A 172 172
LCCH01-333 TC M Meth 71 IA N A 108 108
LCCH01-311 TC M Meth 50 IA N A 91 91
LCCH01-54 TC M Meth, LOH 70 IA N A 47 47
UD-9 TC M Meth 64 IA N A 72 72
UD-10 TC M Meth 74 IA Y D 48 60
UD-11 TC F Meth 63 IA N A 60 60
UD-19 TC F Meth 65 IB N A 48 48
UD-25 TC M Meth 65 IA N A 24 24
AC, Atypical Lung Carcinoid; TC, Typical Lung Carcinoid. 1 LOH, (L) is defined if the allelic imbalance value
(QLOH) is ≤0.05. Meth, KEAP1 promoter methylation; mos, months; F, Female; M, Male; D/A, Dead/Alive; OS,
Overall Survival; DFS, Disease Free Survival.
Patients’ clinical-pathological features analyzed into the study are summarized in Table 2. Overall,
the series included 47 patients grouped in 30 TC (64%) and 17 AC (36%). The average patient’s age at
the time of diagnosis was 63 years with a range from 29 to 76 years. More than half of the patients
were women (55%). All patients underwent curative surgery and all malignant lesions were subjected
to staging according to the TNM system (2009 classification). The lymph node involvement at the
diagnosis was found only in 5 cases (N1 and N2 patients, 11%). During follow-up, no patients showed
a relapse with distant metastasis. After a median follow-up of 92 months, 6 patients (13%) died (1 with
CT and 5 with AC), whereas 41 (87%) patients were still alive at the last visit.
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Table 2. Clinical and pathological data of lung carcinoid patients cohort.
Characteristics Category All subjects (N = 47)
Age at diagnosis (years, median, IQR) - 63, 19.75
Gender (n,%) Female 26 (55.3%)
Male 21 (44.7%)
Histotype subclassification (n,%) Typical Carcinoid 30 (63.8%)
Atypical Carcinoid 17 (36.2%)
T (n,%) T1 31 (67%)
T2 15 (33%)
N (n,%)
N0 41 (89.1%)
N1 3 (6.5%)
N2 2 (4.4%)
M (n,%) M0 47 (100.00%)
Tumour stage (n,%) IA - IB 42 (89.4%)
IIA - IIB - IIIA 5 (10.6%)
Data are reported as frequencies and percentages. mos, months.
The epigenetic status of KEAP1 was correlated to clinical-pathological features of both typical and
atypical lung carcinoids. No significant correlation was found (Tables 3 and 4). Time-to-event analysis
was based on 8 events for disease-free survival and 6 events for overall survival.
Table 3. Clinical pathological characteristics for patients with typical carcinoid (n = 30), according to.
their KEAP1 methylation status.
Characteristics Category UM M p-Value *
Age at diagnosis (years, median
(range)) - 63 (30–76) 64 (29–74) 0.755
Tumor_size (mm, median (range)) - 25 (10–40) 20 (10–45) 0.775
Gender
Female 11 (73%) 6 (40%)
0.07
Male 4 (27%) 9 (60%)
T
T1 10 (71%) 11 (73%)
1.000
T2 4 (29%) 4 (27%)
N
N0 13 (93%) 15 (100%)
0.483
N1 1 (7%) 0 (0%)
M M0 15 (100%) 15 (100%) n.a.
Tumor stage IA - IB 14 (93%) 15 (100%) 1.000
IIA-IIB-IIIA 1 (7%) 0 (0%)
Data are reported as frequencies and percentages. * p-value from two-sample Mann Whitney test and Fisher exact
test for continuous and categorical variables, respectively. UM = unmethylated; M = methylated. n.a. = not analyzed
Univariate time-to-event analysis showed no significant association between the epigenetic status
of KEAP1 and risk of progression (HR = 3.122; 95% CI 0.630–15.474, p = 0.163) and no significant
association between the epigenetic status of KEAP1 and risk of death (HR = 1.769, 95% CI 0.316–9.917,
p = 0.517), (Supplementary Figure S1). Similar results were obtained in the analysis stratified by
histological subtype (Typical vs. Atypical).
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Table 4. Clinical pathological characteristics for patients with atypical carcinoid (n = 17), according to
their KEAP1 methylation status.
Characteristics Category UM M p-Value *
Age at diagnosis (years, median
(range)) — 53 (40–70) 64 (35–71) 0.736
Tumor size (mm, median (range)) — 20 (10–48) 32.5 (20–60) 0.132
Gender
Female 5 (56%) 4 (50%)
1.000
Male 4 (44%) 4 (50%)
T
T1 7 (78%) 3 (38%)
0.153
T2 2 (22%) 5 (62%)
N
N0 7 (78%) 6 (75%)
0.133N1 2 (22%) 0 (0%)
N2 0 (0%) 2 (25%)
M M0 9 (100%) 8 (100%) n.a.
Tumor stage IA-IB 7 (%) 6 (%) 0.893
IIA-IIB-IIIA 2 (%) 2 (%)
Data are reported as frequencies and percentages. * p-value from two-sample Mann Whitney test and Fisher exact
test for continuous and categorical variables, respectively. UM = unmethylated; M = methylated. n.a. = not analyzed
3. Discussion
Lung Carcinoids belong to the heterogeneous group of malignancies characterized by an indolent
rate of growth and progression with a genetic pattern that contains lesions in the classical oncogenes or
tumor suppressor genes identified in NSCLCs [13]. By contrast, carcinoids show frequent mutations
in chromatin remodeling genes, although molecular alterations are rare in general, suggesting the
presence of alternative pathogenic drivers. Epigenetic landscape and promoter methylation events
are poorly investigated in lung carcinoids and only few genes were described to date to be involved
in this specific context [12]. RASSF1 promoter hypermethylation was found as the most frequent
epigenetic event reported in both typical and in atypical lung carcinoids and it was associated with
tumor grade but without a linear correlation between levels of methylation and RASSF1A mRNA
or protein content [14]. MCAM methylation levels were found to be significantly higher in lung
typical carcinoids tumors and were proposed as a useful new molecular biomarker in this tumor
type [15]. Finally, in a small series of 5 low-grade lung NETs, aberrant methylation at the 5′-region of
the p15INK4b gene was observed in 15% of tumors, but not in normal bronchial tissues [16].
To counteract oxidative stress cells, we developed efficient mechanisms of defense. One of the
most important mechanisms involves the activation of the Keap1/Nrf2/ARE pathway. NRF2 is a
transcription factor that coordinates the transiently cellular redox changes and modulates the cellular
defense against toxic and oxidative damage, mitochondrial physiology, differentiation and stem cell
maintenance [17]. Upon exposure to stress, NRF2 translocates into the nucleus, where it binds to the
antioxidant response element (ARE) located in the promoter regions of many cytoprotective genes
such as drug-metabolizing enzymes and antioxidant systems which require NADPH as a cofactor,
including aldo-ketoreductase family 1 member C1 (AKR1C1), NAD(P)H:quinone oxidoreductase-1
(NQO1) and thioredoxin reductase (TXNRD1) [18,19]. The deregulation of this pathway along with
an increased NRF2 activity was firstly described in NSCLC cells, but was quickly confirmed in
many solid tumors. A lot of molecular mechanisms were described to be linked to KEAP1/NRF2
deregulation, such as somatic mutations in NFE2L2, KEAP1 or CUL3 genes; promoter methylation
of KEAP1; microRNA-mediated regulation of KEAP1 and NRF2 [2]. Frequent LOH was observed
in at 19p13.2, thus confirming the role of KEAP1 as a tumor suppressor gene [3,6]. Despite of the
widely investigations of this pathway in NSCLC and the observed link between many NRF2 target
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proteins and lung neuroendocrine tumors (lung carcinoid and SCLC), few studies were performed to
investigate the link between lung carcinoid and oxidative stress (Table 5), [20].
Table 5. NRF2-interacting proteins identified in lung carcinoids.
Protein Name (symbol) Reference
NAD(P)H dehydrogenase (quinone 1) (NQO1) [21], this report
Aldo-Keto Reductase Family 1 (AKR1) (AKR1C1) [22], this report
Hemoglobin subunit beta (HBB) [23,24]
Ferritin light chain (FTL) [24,25]
Ferritin heavy chain (FTH) [24,26–29]
Superoxide dismutase (SOD) [24,30–35]
Extracellular Superoxide dismutase (SODE) [24,36,37]
Carbonic Anhydrase 1 (CAH1) [24,38]
Annexin V (ANXA5) [24,39,40]
Peroxiredoxin-2 (PRX2) [24,41–43]
Peroxiredoxin-3 (PRX3) [24,42,44,45]
Transthyretin (TTR) [24,46]
Hemopexin (HPX) [24,47]
Transaldolase (TALDO) [24,48]
Heterogenous Nuclear Ribonucleo protein K (HNRPK) [24,49,50]
Histone H4 [24,51–54]
Heat Shock Protein Hsp90-alpha (HSP90) [24,55–57]
Elongation Factor 1-alpha1 (EF1A1) [24,58]
Here we describe the results obtained from the first comprehensive genetic and epigenetic profile
of KEAP1 and NFE2L2 genes in a collection of lung carcinoid tumors. No mutations were identified in
our cohort, so we can clearly exclude a driver contribution by these type of molecular lesions in this
lung NETs. Data produced were in fact similar to those reported by the unique WES study performed
to date by Simbolo et al. [9] in a total of 44 cases (23 TC and 14AC samples), and by three previously
large published studies [59]. By contrast, the KEAP1 genetic alterations appear to be strongly related to
a high-grade lung NET. Specifically, Fernandez-Cuesta et al. described KEAP1 point mutations as a
specific molecular event associated with pulmonary LCNECs with adenocarcinoma-like features [7].
This last finding was confirmed by a different group which reported a prevalence of KEAP1-NFE2L2
(31%) alterations in tumors with high neuroendocrine gene expression, mainly co-occurring with STK11
and KRAS genes to exert a synergic role of tumorigenesis enhancement and cancer progression [60].
We decided to investigate the effect of KEAP1 silencing in lung carcinoids by performing functional
investigation in H720 and H727 cell lines. The KEAP1 silencing studies by siRNAs performed both
in H720 and in H727 cell lines strongly indicate that KEAP1 is also a master regulator of NRF2 in
lung carcinoids cells. Since NRF2 coordinates the regulation of detoxification and intracellular redox
balance in response to oxidative stress, some of the NRF2 targets such as TXNRD1, AKR1C1, and
NQO1 have been functionally chosen which are well-known implicated in drug and/or radiation
resistance contexts of solid tumors [61]. NQO1 has attracted much attention as a potential target for
the treatment of cancer because it has been shown to be frequently expressed at much higher levels in
tumors, mainly in lung tumors, relative to adjacent non-neoplastic tissue regions. In addition, NQO1
activity appears to be increased during tumor progression. A clear modulation by KEAP1 on these
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NRF2-target proteins has been observed and confirms the control activity by KEAP1 protein to the
detoxifying pathway NRF2-related in carcinoids cells.
A direct correlation between KEAP1 epigenetic silencing and transcript level was also
demonstrated in the KEAP1 hypermethylated H720 cell line under the demethylating treatment
with 5-aza-2-deoxycytidine. As previously reported in other tumors, a clear recovery of the KEAP1
transcription level was in fact observed and confirmed the inverse correlation between KEAP1
expression and CpGs island hypermethylation [2]. The epigenetic silencing by KEAP1 hypermethylation
in lung carcinoids was then investigated in carcinoid tissues from 47 patients. As results, aberrant
KEAP1 methylation of the gene P1 promoter region [4,13] was identified in both TC and AC samples at
a high frequency of about 50% without any significant difference in methylation levels detected by
comparing TCs with ACs. LOH at the gene locus was also demonstrated in 50–60% of the tumors.
Overall 24% of the tumors showed two alterations (LOH and promoter methylation) in KEAP1,
suggesting that both copies of the gene might be inactivated.
The concordance between methylation levels and protein expression was also investigated by
immunohistochemical analysis in 11 tumor cases showing KEAP1 promoter methylation (3 AC and 8
TC) and 3 TCs without methylation. A variable KEAP1 and NRF2 immunoreactivity were observed
in the cytoplasm of tumor cells, but no statistically significant difference was appreciated. Only in
a few cases was it possible to notice a direct relationship between KEAP1 down-regulation and
overexpression of NRF2 and its targets NQO1 and TXNRD1 but data were not adequate to provide
any conclusions. The lack of correlation between KEAP1 methylation and protein levels should be
mainly explained taking into account that 1) other transcriptional or post-transcriptional events may
concur in KEAP1 regulation; 2) It is plausible that the use of a non-specific qMSP assay does not
allow us to discriminate among really functional and non-functional CpGs of the P1 promoter island,
since it covers simultaneously all the CpGs of KEAP1 P1 promoter region, so it should be difficult to
appreciate the effective functional level of methylation to correlate with protein expression. From a
translational point of view, these considerations should also justify the lack of a clear correlation
between methylation and disease course, both in TC and AC. Currently, there is no consensus on
the best technique for KEAP1 methylation assessment. How many and which CpG sites of KEAP1
promoter should be analyzed remains a controversial issue in a translational context [2]. However, a
more strong impact on KEAP1 expression level should be hypothesized for the CpG sites located in
the critical sub-region closer to the transcription start site (TSS) of KEAP1 gene which contains putative
binding sites for Sp1 and AP2 transcription factors [22,52,53].
Despite all these considerations, the KEAP1 silencing studies support the hypothesis that KEAP1
acts in lung carcinoids by modulating the levels of NRF2 and the NRF2-detoxification enzymes
TXNRD1 and NQO1.
Looking at a possible correlation between methylation and clinic-pathological parameters, it was
observed that the degree of promoter methylation showed a trend of association with a higher risk
of progression, which is difficult to confirm due to the indolent course of disease of lung carcinoid
and a large number of cases required for a validation in an independent cohort. Anyhow, the general
observation of a deregulation of KEAP1/NRF2 axis in lung carcinoid provided the opportunity to
consider new therapeutic approaches that directly involve epi-drugs or drugs affecting redox processes
to support the chemo and radio-therapeutic options strictly related to the generation of ROS [62].
More interestingly, it should be noticed that the NRF2 is a master transcription factor that regulates
a wide variety of cellular proteins and recently it has been reported to indirectly up-regulate mTOR
activity by increasing the intermediary protein RAGD, an activator of mTOR and positively modulate
the transcription of mTOR in cells with abnormally active PI3K signaling [63,64]. The link between the
NRF2 system of sensing environmental stress and mTOR may suggest a possible role of KEAP1/NRF2
deregulation observed in lung carcinoids in prediction to response to mTOR pharmacological inhibition
in these tumors [65]. On the other hand, the high prevalence of the PI3K pathway deregulation in
cancer cells could offer the opportunity to selectively modulate this pathway via NRF2 in non-tumor
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cells, an approach that deserves exploration [5,66]. Finally, it must be take into account that NRF2 levels
can be regulated in a KEAP1-indipendent way by carcinoid tumor-related oncogenes, so their profile
should impact and must be monitored to predict a tumor response to pharmacological treatments [67].
Actually, some chemicals were also reported as NRF2 modulators, although the molecular
mechanisms through which these compounds inhibit NRF2 were not been fully elucidated. Since NRF2
inhibitors are well-known as suppressors of the proliferation of cancer cells, many questions related to
the NRF2 inhibitors remain unsolved about the real utility in clinical trials, especially in the context
of lung cancer. Many NRF2 modulators were discovered by starting from natural compounds, such
as brusatol [68] which contributes to the decrease of NRF2 expression at both transcript and protein
levels in the abovementioned cells, luteolin (3′,4′,5,7-tetrahydroxyflavone), [69] and all trans-retinoic
acid (ATRA), an active metabolite of vitamin A, which represses NRF2 activity by inhibiting its
capability to bind to ARE sequences of its target genes [70]. In addition, semisynthetic and synthetic
compounds were investigated in clinical trials, such as ML385, a thiazole-indoline compound which
targets the DNA-binding region of NRF2 protein (Neh1 domain) and successively inhibits the activation
of its downstream target genes. In preclinical models of KEAP1 mutated lung cancer cells, it was
observed that ML385 plus carboplatin enhances the efficacy of anti-tumor activity of chemotherapic
compounds [71]. Clobetasol propionate was identified as the most potent Nrf2 inhibitor with strong
in vivo and in vitro effects on the suppression of the anchorage-independent growth of lung tumors
harboring KEAP1 mutations, alone or in combination with rapamycin [72].
In general, there are no currently specific inhibitors of NRF2 available in clinical practice of
lung cancer patients to pharmacologically target NRF2 pathway because of all of them show poor
results for anticancer therapy and additional studies are needed to gain insights into the mechanism of
Nrf2 modulation.
4. Methods
4.1. Cell Lines
The H720 atypical carcinoid cell line and the H727 typical carcinoid cell line were purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA) and ECACC (Porton Down, Salisbury,
UK), respectively. Cells were cultured in RPMI 1640 medium, supplemented with 10% FBS.
4.2. KEAP1 Silencing by siRNA
KEAP1 siRNA duplexes specific for human gene KEAP1 (NM_012289) were purchased from
Thermo Scientific (Carlsbad, CA, USA), (Silencer Select, s18981). A scrambled siRNA was used as
a negative control (CTRL siRNA), (Silencer Select, Negative Control) and purchased from Thermo
Scientific. RNA interference (RNAi) experiments in carcinoid cells were performed by transient
transfection for 48h. The RNAiMAX Lipofectamine (Thermo Fisher, Invitrogen) transfection protocol
was used. Cells were analyzed for KEAP1 expression by Western blot analysis after 48 h.
4.3. Western Blot Analysis
Cells were lysed with RIPA buffer and proteins were separated on 13% SDS-PAGE and transferred
onto a PVDF membrane. The membrane was stained immunochemically using anti-KEAP1, NRF2,
NQO1, TXNRD1 (Proteintech, Chicago, IL, USA), and by using anti-AKR1C1 (Abnova, Taiwan).
H720 and H727 cells were cultured in RPMI 1640, supplemented with 10% FBS and antibiotics.
Equal amounts of protein lysates (35 µg) were resolved by SDS-PAGE (13% acrylamide) under
reducing conditions and transferred onto PVDF membranes (Immobilon PVDF, Millipore, Billerica,
MA, USA). After transfer, PVDF membranes were blocked with 5% non-fat milk and incubated with
primary antibody overnight at 4 ◦C. Rabbit anti-NRF2 (Proteintech), rabbit anti-NQO1 (Proteintech),
rabbit anti-TXNRD1 (Proteintech), mouse anti-AKR1C1 (Abnova) and anti-Actin (Sigma-Aldrich, St.
Louis, MO, USA) were incubated overnight at 4 ◦C. PVDF membranes were incubated with ECL
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plus solution following the manufacturer’s instructions (Thermo Fisher Scientific, Rockford, IL, USA).
Chemiluminescence signals were acquired by ChemiDoc XRS (Biorad, Hercules, CA, USA).
4.4. In Vitro 5-Aza-2′-deoxycytidine (5-aza-dC) Treatment
Treatment with the 5-aza-2′-deoxycytidine (DAC), was performed using a concentration of 5µM
(Sigma-Aldrich) with fresh medium for 24 h and 48 h. Cells were harvested at both time points for
DNA and RNA isolation to perform KEAP1 methylation and gene expression analysis.
4.5. RNA Extraction, Reverse Transcription and Quantitative Real-Time PCR (qRT-PCR)
RNA quality was measured by using 2100 Expert Analyzer (Agilent Technologies, Santa Clara,
CA, USA) and RNA with RIN (RNA Integrity Number) ≥7.0 was processed. RNA concentrations were
quantified by the Nanodrop spectrophotometer. cDNA was synthesized from 1 µg of total RNA using
SuperScript III (Thermo Fisher, Invitrogen division) and qRT-PCR was by TaqMan® Universal PCR
Master Mix (Thermo Fisher, Life Technologies division), and TaqMan™ Gene Expression Assay with
specific TaqMan probe assay (listed in Supplemental Table S1) on ABI PRISM 7900 Sequence detection
system (Thermo Fisher, Applied Biosystems). Serial dilutions (1 × 106–1 × 102 copies) of plasmid
product were used to build a standard curve and mRNA levels in each sample were determined using
a relative quantification method as the ratio of the KEAP1 expression level to the RPLPO expression.
4.6. Patients and Tissue Samples
The patients’ clinical and pathological data including pathological TNM staging, site of the lesion,
grading, age, gender, and follow-up data were collected and are shown in Table 2.
We analyzed lung carcinoid tissues obtained as fresh frozen specimens/FFPE tissues from a total
of 47 patients (30 Typical Carcinoids and 17 Atypical Carcinoids) surgically treated at IRCCS Casa
Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy and Santa Maria della Misericordia”, Udine,
Italy. As control, 12 histologically confirmed normal lung tissues distant from tumor were analyzed.
All tissue specimens from patients were fixed in neutral-buffered formalin prior to paraffin
embedding (FFPE samples). Sections, 3-µm-thick, were cut from FFPE tissue blocks and marked
by a pathologist on H&E-stained slides to verify tumor cellularity. DNA was extracted from
corresponding unstained 12-µm-thick section by manual microdissection and subsequently isolated by
using GeneRead FFPE Kit (Qiagen, Germantown, MD, USA) following the manufacturer’s instructions.
Eluted DNA was assessed for purity using the Thermo Scientific NanoDrop™ 1000 Spectrophotometer,
and double-stranded DNA was quantified using the Qubit Fluorometer (Thermo Fisher, Carlsbad,
CA, USA).
4.7. Bisulfite Conversion and Quantitative Methylation Specific-PCR Analysis (qMSP)
Sodium bisulfite modification and purification of DNA extracted from cell lines and tumor
samples were performed by using EpiTect Bisulfite kit (Qiagen) according to manufacturer’s instruction.
Bisulfite-converted genomic DNA was amplified using qMSP. Primers/probe sets were designed to
cover the unmethylated promoter region of the ACTB gene used as a reference gene as described
previously [73] and are listed in Supplemental Table S2.
Ten-fold dilutions for four points (50–0.05 ng) of enzymatically methylated human genomic DNA
(CpGenomeTM Universal Methylated DNA, Millipore, Bedford, MA, USA) were used to construct a
calibration curve for ACTB (reference) and KEAP1 (target) genes. qMSP reactions were performed
in 384-well plates in triplicate and loaded on an ABI PRISM™ 7900HT Sequence Detection System
(Thermo Fisher, Carlsbad, CA, USA) and SDS 2.4 software (Thermo Fisher, Applied Biosystems
division) was used to analyze the runs. Relative methylation levels were calculated for each sample by
dividing the average value from the triplicates between KEAP1 and ACTB.
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4.8. Mutation Analysis And Loss of Heterozygosity Analysis (LOH)
DNA obtained from the 47 carcinoid tumors of the lung was analyzed by fluorescence-based
direct sequencing for the entire KEAP1 gene coding region, including exon-intron boundaries and for
the exon 2 of NFE2L2 gene (Supplemental Table S3) as previously described [3]. Sequences were read
with an ABI 3100 sequence detection system and analyzed using the Sequencing Analysis software
v.3.7 (Thermo Fisher, Applied Biosystems). LOH analysis was performed using four microsatellite
markers flanking the KEAP1 [3] and products were genotyped using a ABI 3100 sequence detection
system (Supplemental Table S4). Allele sizes were scored by ABI Genescan and Genotyper Software 3.7
(Thermo Fisher, Applied Biosystems division). LOH or allelic imbalance (AI) values were calculated
using the following formula: (peak 1 height/peak2 height in tumor DNA)/(peak 1 height/peak 2 height
in normal DNA) using a value of 0.5 to define LOH/AI [65].
4.9. Immunohistochemistry (IHC)
FFPE sections of 16 carcinoids (3 AC and 13 TC) were selected for IHC analysis using different
antibodies (Supplemental Table S5). Detection was made by using EnVision TMFLEX+ detection kit
(Dako, Glostrup, Denmark) following the manufacturer’s protocol and results were evaluated using
the Olympus BX51 microscope. KEAP1 protein expression was evaluated for cytoplasm reactivity in
tumor cells using a semi-quantitative system which combined staining intensity and the percentage of
positive neoplastic cells. A final immunoreactivity staining score (IRS) was obtained by adding the
score of percentage positivity and intensity. Samples were classified ad negative/weak staining (IRS
<2) and moderated/strong staining (IRS ≥2).
4.10. Statistical Analysis
Patients baseline characteristics were reported as median and range or frequencies and percentages
for continuous and categorical variables, respectively. Baseline comparisons between groups according
to KEAP1 methylation status were made using the Fisher or chi-square test for categorical variables,
and the Mann-Whitney U-test for continuous variables.
Progression-free survival was defined as the time between surgery and the first progression,
or death without progression, or date of last follow-up visit for patients alive without progression.
We calculated median follow-up according to the reverse Kaplan-Meier technique [72]. Overall survival
was defined as the time between surgery and death, or date of last follow-up visit for alive patients.
Survival curves were estimated using the Kaplan–Meier method and significance was assessed with a
log-rank test. Furthermore, univariate Cox proportional hazards regression models were estimated,
both unadjusted and stratified by histological subtype. Risks were reported as hazards ratios (HR)
along with their 95% confidence interval (CI).
Comparison of the mRNA expression level of NRF2-target enzymes between carcinoids cells lines
and the expression levels of the proteins normalized to actin was performed using two-tailed Student’s
t-test. Correlation between RT-qPCR and Western blot data was assessed by Pearson’s correlation
coefficient. Experiments were repeated three times and representative experiments are shown. In the
histograms, the values are presented as means ± standard error of the mean (SEM). Student’s t-test for
unpaired data was used.
A p-value <0.05 was considered for statistical significance. All analyses were performed using
SAS Release 9.1 (SAS Institute, Cary, NC, USA) and with SPSS for Windows, Version 24.0.
For densitometry analysis, the images were analyzed using ImageJ Software. For relative
quantification, the optical density value was determined for same sized boxes drawn around
antibody-stained bands. Normalization was performed using β-Actin antibody staining bands.
The association between IHC and methylation was tested using t-test.
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5. Conclusions
In conclusion, our findings of KEAP1 methylation and related NRF2 pathway deregulation in lung
carcinoids add important data to the poorly uncovered epi-profile of lung NET. Validations of these
results are needed in larger studies to find a clear link with the patient’s follow-up and stratification.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/10/
2531/s1.
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